DragonFly System Obtains Commercial Approvals in Panama and Jordan

HANGZHOU, China — Valgen Medtech announced that its proprietary DragonFly System has officially obtained regulatory approvals for commercial marketing and clinical use in both Panama and Jordan.

With these commercial approvals, the DragonFly™ System can now provide local physicians and patients with a safe, precise, and minimally invasive mitral valve repair solution to effectively treat mitral regurgitation.

This simultaneous market entry into Central America and the Middle East marks another major milestone in Valgen Medtech’s global commercialization. As a leading transcatheter mitral valve clamping system, the DragonFly™ System continues to expand its global commercial footprint, bringing validated clinical performance to international markets.

This milestone further drives Valgen Medtech’s compliant international growth, advancing its mission to deliver world-class, commercialized structural heart solutions to healthcare systems worldwide.